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Abstract
Background—The prevalence of severe obesity, often considered a contraindication to 
peritoneal dialysis (PD), has increased over time. However, mortality has decreased more rapidly 
in the PD population than the hemodialysis (HD) population in the United States. The association 
between obesity and clinical outcomes among patients with end-stage kidney disease remains 
unclear in the current era.
Study Design—Historical cohort study.
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Setting & Participants—15,573 incident PD patients from a large US dialysis organization 
(2007–2011).
Predictor—Body mass index (BMI).
Outcomes—Modality longevity, residual renal creatinine clearance, peritonitis, and survival.
Results—Higher BMI was significantly associated with shorter time to transfer to HD (P for 
trend <0.001), longer time to kidney transplantation (P for trend <0.001), and, with borderline 
significance, with more frequent peritonitis-related hospitalization (P for trend =0.05). Compared 
to lean patients, obese patients had faster declines in residual kidney function (P for trend <0.001), 
and consistently achieved lower total Kt/V over time (P for trend <0.001) despite greater increases 
in dialysis Kt/V (P for trend <0.001). There was a U-shaped association between BMI and 
mortality, with the greatest survival associated with the BMI range of 30–<35 kg/m2 in the case-
mix adjusted model. Compared to matched HD patients, PD patients had lower mortality for BMI 
<35 kg/m2 (P for interaction =0.1 for BMI 25–<35 [versus <25] kg/m2) and had equivalent 
survival in the BMI category ≥35 kg/m2 (P for interaction =0.001). This attenuation in survival 
difference among patients with severe obesity was only observed in patients with diabetes, but not 
in those without diabetes.
Limitations—Inability to evaluate causal associations. Potential indication bias.
Conclusions—Whereas obese PD patients had a higher risk of complications than non-obese 
PD patients, their survival was no worse than matched HD patients.
Keywords
peritoneal dialysis (PD); hemodialysis (HD); obesity; diabetes; mortality; survival advantage; 
technical failure; technical survival; peritonitis; residual kidney function (RKF); creatinine 
clearance (CLcr); kidney transplantation; obesity paradox; dialysis modality; end-stage renal 
disease (ESRD); renal replacement therapy (RRT)
The prevalence and severity of obesity among patients with end-stage renal disease (ESRD) 
has increased over time since the mid-1980s in developed countries.1 This epidemic has 
occurred in parallel with trends in the general population, but has been more dramatic 
among patients with ESRD in the United States.2–4 This difference in the observed secular 
trends of obesity can be explained by the heightened risk of chronic kidney disease among 
obese patients and those with diabetes,5,6 and also by the “obesity paradox” of ESRD 
patients in whom obesity is unexpectedly associated with greater survival.7–10
Interestingly, whereas the obesity paradox has consistently been observed among ESRD 
patients on hemodialysis (HD), there are inconsistent data among those receiving peritoneal 
dialysis (PD).11–17 It is generally thought that dialysis clearance may be less adequate in 
obese PD versus HD patients due to less efficient solute and fluid removal, although a small 
observational study has shown feasibility of achieving adequate solute clearance in obese PD 
patients.18 Other studies have shown that obesity is associated with higher risk of peritonitis 
and more rapid decline in residual kidney function,19,20 both important risk factors for death 
and transfer to HD.21–23 Indeed, a previous study of US Renal Data System (USRDS) data 
demonstrated that PD patients with obesity, defined as those with BMI ≥30 kg/m2, showed 
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faster transfer to HD yet similar survival compared to PD patients without obesity.14 
Furthermore, among ESRD patients who are obese, receipt of PD has been associated with 
equivalent or higher mortality as compared with receipt of HD.24,25 These data have 
discouraged nephrologists from recommending PD as a treatment option for obese ESRD 
patients,26,27 and some facilities have listed severe obesity as a contraindication to PD.28–32
However, most of these data were derived from non-contemporary cohorts who may not be 
generalizable to present-day dialysis populations. Mortality has decreased more rapidly in 
the PD versus HD population in the United States,4,33 likely due to advances in PD delivery, 
efficacy, and safety over the past two decades. Indeed, there is a progressive attenuation in 
mortality risk associated with PD in more recent cohorts.34 Nevertheless, it remains unclear 
if these advances have influenced the association between obesity and clinical outcomes in 
the current era. Thus, we hypothesized that the severity of obesity, expressed as body mass 
index (BMI), is incrementally associated with adverse clinical outcomes, and that the 
survival advantage of PD is attenuated among obese ESRD patients.
METHODS
Patients
We retrospectively extracted, refined, and examined data from all incident ESRD patients 
who were aged 18 years or older in facilities operated by a large dialysis organization in the 
United States from January 1, 2007 through December 31, 2011.35 Data used for analyses 
were de-identified. We selected patients who underwent PD more than 1 day during the 
follow-up period. We then excluded patients without data on BMI or residual renal 
clearances of urea and creatinine during the first 91 days of PD (Figure 1). We further 
excluded patients with weekly renal creatinine clearance >300 L/1.73 m2. Differences in 
characteristics at PD initiation between included versus excluded patients were compared by 
standardized differences due to the relatively large sample size of this study (Table S1, 
available as online supplementary material).36,37
This study was approved by the Institutional Review Committees of the Los Angeles 
Biomedical Research Institute at Harbor-UCLA, University of California Irvine Medical 
Center, and the University of Washington with the exemption of obtaining written consent 
given the large sample size, anonymity of the patients studied, and nonintrusive nature of the 
research.
Demographic, Clinical, and Laboratory Measures
All information were obtained from the electronic database of the dialysis provider. Blood 
samples were drawn using uniform techniques in all dialysis clinics and were transported to 
a central laboratory in Deland, Florida, typically within 24 hours. To minimize measurement 
variability, all repeated measures for each patient during the first quarter (or 91 days) of PD 
were averaged and then used as baseline data in all analyses. We calculated residual renal 
creatinine clearance (ClCr) as the average of renal urea and creatinine clearances, indexing 
to body surface area.38 Actual body weight, not ideal body weight, was used to calculate 
Kt/V.
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BMI was categorized in six groups (<20, 20–<25, 25–<30, 30–<35, 35–<40, and ≥40 kg/
m2). Given the established cardiovascular risk profiles among HD patients, severe obesity 
was defined as a BMI of ≥35 kg/m2.39
Statistics for Clinical Outcomes Among Patients Receiving PD
Patients were followed up from their first day of PD until their death or 60 days after transfer 
to HD or kidney transplantation (KTx). The outcomes of interest were all-cause death, 
transfer to HD, KTx, peritonitis-related and non-peritonitis-related hospitalization, and 
trajectories of solute clearance indices (i.e., renal ClCr and renal, peritoneal, and total 
weekly Kt/V). Transfer to HD was defined as not undergoing PD for ≥60 days.
The associations of the BMI categories with the competing outcomes of death, transfer to 
HD, and KTx were examined in the entire PD cohort using cause-specific hazards models by 
treating competing events as censoring. Proportional hazards assumptions were tested using 
log-log plots and Schoenfeld residuals. The associations with peritonitis-related and non-
peritonitis-related hospitalization were also examined by the negative binominal regression 
model.
Models were examined with three-level sequential adjustments as follows: 1) Unadjusted 
model that included the BMI categories only; 2) Case-mix adjusted model that included age, 
sex, race/ethnicity, cause of ESRD, six comorbidities in Table 1, log-transformed dialysis 
vintage, and log-transformed 5-year cumulative number of incident PD patients treated per 
facility (as a proxy for "PD facility experience"); and 3) Fully adjusted model which 
included all of the covariates in the case-mix model plus log-transformed weekly renal ClCr, 
weekly peritoneal Kt/V, normalized protein nitrogen appearance (nPNA), and six laboratory 
variables in Table 1. The case-mix adjusted model was a priori defined as the primary model 
given the potential over-adjustment in the fully adjusted model.
In order to examine the association of BMI with change in solute clearance indices over 
time, patient follow-up time was divided into quarters (or 91-day periods) from date of PD 
initiation up to two years, and we used the linear mixed-effects models with random 
intercept and slope using unstructured covariance matrices. Each of quarterly-averaged 
values in solute clearance indices served as the outcome, and we included the BMI 
categories, case-mix variables, and the interaction terms between quarters and the BMI 
categories. The interaction terms represent differences in the slopes from baseline.
Statistics for Mortality Comparison Between HD and PD
In order to evaluate whether the severity of obesity affects the between-modality difference 
in KTx-free mortality, we matched PD patients to HD patients in a 1:2 ratio using nested 
matching with replacement based on age (within ±2.5 years), sex, race/ethnicity, ESRD 
reason, dialysis vintage, the six aforementioned BMI categories, and Deyo-Charlson 
comorbidity index categories (2, 3–4, 5, 6, ≥7).40 In short, except for those who were ever 
treated with either home HD, infrequent HD, less frequent HD, or nocturnal HD, we 
identified the number of days from dialysis initiation to PD initiation (vintage day) for each 
PD patient. Each PD patient was then matched to two patients who were treated with HD at 
the same dialysis vintage regardless of whether or not matched patients initiated PD later on 
Obi et al. Page 4
Am J Kidney Dis. Author manuscript; available in PMC 2019 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
(as per the intention-to-treat principle). All patients were followed up from this matched 
vintage day. Matching with replacement generally decreases bias.41 The average of pre- and 
post-HD weight was used to calculate BMI among HD patients in order to minimize the 
influence of body fluid dynamics. Among 7,412 patients who were treated with HD and PD 
in the same quarter of dialysis and who had data on BMI during both modality periods, the 
within-individual difference in BMI was 0.0±1.3 kg/m2. Laboratory variables were not 
included for this analysis because they were considered intermediating factors.
The matched cohort of 14,007 PD patients and 28,014 matched HD patients totaled 42,021 
patients, and comprised 40,289 individual patients. Patients were followed up even after 
switching dialysis modality but censored at loss-to-follow-up, or December 31, 2011. KTx 
was a competing event and treated as censoring in cause-specific hazards models. For 
calculating the difference in cumulative mortality between HD and PD over time, BMI was 
categorized into just 3 groups (<25, 25–<35, and ≥35 kg/m2) in order to ensure adequate 
sample sizes. Given violation of the proportional hazard assumption by treatment modality 
(i.e., PD vs. HD), the statistical significance of effect modification by BMI category was 
evaluated by their interaction terms with PD in the cause-specific hazards models including 
the interaction term between PD and log-transformed time. In subgroup analyses, the 
cumulative mortality and its between-group differences were provided with their 95% 
bootstrap confidence intervals (CIs) based on 1,000 bootstrap sampling. Given that the 
prevalence of diabetes, an established effect modifier of the association between dialysis 
modality and mortality,42–44 was incrementally higher across increasing BMI categories, we 
further stratified patients according to diabetes.
Linear assumptions among covariates were examined using restricted cubic spline functions 
and a likelihood ratio test for goodness of fit.45 Missing baseline data were 4% for dialysis 
facility and intact PTH and <1.2% for the remaining laboratory variables (Table S2), and 
were imputed by respective median values. Missing longitudinal data on solute clearance 
indices (~30% after the second quarter) were not imputed in mixed-effects models. Analyses 
were conducted using STATA MP version 13.1 (StataCorp, College Station, TX) and SAS 
version 9.4 (SAS Institute Inc., Cary, NC).
RESULTS
Baseline Demographic, Clinical, and Laboratory Characteristics
The mean age in the entire PD cohort was 56±15 (standard deviation) years, among whom 
58% were male, 58% were non-Hispanic white, 22% were non-Hispanic black, and 62% had 
diabetes (Table 1). Their median BMI was 28 (interquartile range [IQR], 24–32) kg/m2, and 
the prevalence of BMI categories <20, 20–<25, 25–<30, 30–<35, 35–<40, and ≥40 kg/m2 
was 5.5%, 26%, 32%, 21%, 10%, and 5.5%, respectively. Patients with higher BMI had 
greater renal ClCr and lower peritoneal ClCr, and there was a significant trend toward 
greater total ClCr across higher BMI. Meanwhile, renal Kt/V was not different across these 
BMI categories but patients with higher BMI showed lower peritoneal Kt/V, resulting in 
lower total Kt/V.
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Association of BMI With Clinical Outcomes and Change in Renal ClCr
During the follow-up period, 2,568 patients transferred to HD. A total of 1,863 patients died 
while 1,271 underwent KTx during the follow-up period including 90 days after transferring 
to HD. The incidence rates of these outcomes across the six BMI categories are shown in 
Figure 2A. Patient characteristics during the last quarter of PD are summarized in Table 2, 
according to the outcomes. Specifically, among patients transferred to HD, the median total 
ClCr and total Kt/V during the last quarter of PD were 68 (IQR, 51–93) and 2.0 (IQR, 1.7–
2.5), respectively, and 22% and 23% did not reach the target ClCr and Kt/V, respectively.
There was a trend towards higher risk of transfer to HD across higher BMI categories (Ptrend 
<0.001 for all adjustment models; Figure 2B). In the primary model adjusted for case-mix 
covariates using the “optimal” BMI (i.e., 20 to <25 kg/m2)1 as the reference group, the risk 
for transfer to HD was significantly higher in BMI categories of 35–<40 and ≥40 kg/m2. The 
risk associated with BMI categories of <20 and 25–<30 kg/m2 were not significant in all 
models, while the BMI category of 30–<35 kg/m2 was associated with shorter time to 
transfer to HD in the unadjusted and fully-adjusted models but not in the case-mix adjusted 
mode.
We observed a U-shaped association between BMI and all-cause mortality, with the greatest 
survival in the BMI range of 30–<35 kg/m2 in the case-mix adjusted model (Figure 2C). The 
mortality risk of the lowest of the six BMI categories (i.e., <20 kg/m2) was incrementally 
attenuated with sequential adjustments. Lower mortality risk associated with the higher BMI 
categories (i.e., ≥25 kg/m2) was also attenuated by these adjustments and even reversed in 
the BMI categories ≥35 kg/m2 after adjustment for laboratory variables. Higher BMI showed 
consistent associations with lower likelihood of undergoing KTx across all adjustment 
models, particularly in BMI categories >30 kg/m2 (Ptrend <0.001; Figure 2D).
We then examined the associations of BMI with peritonitis-related and non-peritonitis-
related hospitalizations. There were 2,331 hospitalizations due to peritonitis among 1,315 
patients and 32,723 non-peritonitis-related hospitalizations among 9,442 patients. There was 
a trend towards higher incidence of peritonitis-related hospitalization across higher BMI 
categories in all adjustment models (Ptrend = <0.001, 0.05, and <0.001 in the unadjusted, 
case-mix, and fully adjusted models, respectively; Figure 3A). Conversely, higher BMI was 
associated with lower incidence of non-peritonitis-related hospitalization in the case-mix 
adjusted model (Ptrend <0.001) although this association was not significant in the 
unadjusted and fully adjusted models (Ptrend = 0.8 and 0.9, respectively; Figure 3B).
We also compared changes in solute clearance indices across the six BMI categories. Obese 
patients started PD at higher renal ClCr levels but had faster decline in renal ClCr (Ptrend 
<0.001; Figure 4A). Renal Kt/V was comparable at baseline across BMI categories, but it 
also declined faster among obese patients (Ptrend <0.001; Figure 4B). Obese patients, when 
compared with lean patients, showed lower peritoneal Kt/V at baseline and had greater 
increase in peritoneal Kt/V (Ptrend <0.001; Figure 4C). Consequently, the rate of decline in 
total Kt/V was not different across BMI categories (Ptrend =0.6), and lower total Kt/V among 
obese versus lean patients persisted during two years of PD (Ptrend <0.001; Figure 4D).
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Mortality Among Patients on PD Versus HD by BMI Category
A total of 14,007 PD patients (90%) were matched to 28,014 HD patients using 1:2 
matching based on BMI, age, sex, race/ethnicity, ESRD reason, dialysis vintage, the three 
BMI categories (ie, <25, 25–<35, and ≥35 kg/m2) used for this analysis, and Charlson 
comorbidity index. Patient characteristics are summarized in Table 3. Obese patients tended 
to be younger, female, and non-Hispanic black; were more likely to have diabetes as the 
cause of ESRD; and had higher Charlson comorbidity index scores (Ptrend <0.001 for all). In 
this matched cohort, patients were followed even after changing their treatment modality. 
Among incident PD patients, the proportion of patients still on PD at Year 4 was lowest 
(52%) among patients with BMI ≥35 kg/m2 when compared to those with BMI <25 kg/m2 
versus 25–<35 kg/m2 (i.e., 61% vs. 66%, respectively) (Figure 5A–C). BMI significantly 
modified the association between dialysis modality and mortality (P for interaction =0.01). 
The between-group difference in mortality (HD – PD) increased especially during the first 
year across the three BMI categories, and was 11% (95% CI, 10%–13%), 7% (95% CI, 6%–
8%), and 7% (95% CI, 6%–9%) at Year 1 in the lowest, middle, and highest BMI stratum, 
respectively (Figure 5D–F). While PD patients with BMI <35 kg/m2 consistently showed 
lower mortality for up to four years (Pinteraction =0.1), the survival advantage of PD over HD 
was attenuated over time among patients with BMI ≥35 kg/m2 (versus <25 kg/m2; Pinteraction 
=0.001), and the significant difference was limited to up to 1,250 days.
Additionally, the association between dialysis modality and mortality was further modified 
by diabetes (Pinteraction <0.001). While PD was consistently associated with lower mortality 
among non-diabetic ESRD patients irrespective of BMI strata (Ptrend for interaction =0.6), 
attenuation in the survival difference was observed among patients with diabetes when BMI 
exceeded 35 kg/m2 (Pinteraction = 0.007 [versus <25 kg/m2]; Figure S1).
DISCUSSION
In this large, nationally representative and contemporary cohort of 15,573 incident PD 
patients in the United Sates, we found that higher BMI was associated with shorter time to 
transfer to HD, longer time to KTx, and more frequent peritonitis-related hospitalization, 
and that there was a U-shaped association between BMI and mortality. Obese patients had 
faster decline in residual kidney function, and consistently showed lower total Kt/V over 
time despite greater increase in dialysis Kt/V. When compared to matched HD patients, PD 
patients consistently showed lower mortality if their BMI was <35 kg/m2. However, there 
were no significant differences in mortality between modalities among severely obese 
patients, especially among those who had diabetes.
In previous studies, obesity has similarly been associated with shorter time to transfer to HD,
14,46
 higher risk of peritonitis,19 and faster decline in residual kidney function.20 However, 
most of these prior studies used BMI as a continuous variable or categorized BMI into 2–3 
groups, limiting their ability to detect a threshold of BMI where risk starts to increase. The 
large sample size of this study enabled us to examine more granularly-defined BMI 
categories, and we found that in BMI categories ≥30 kg/m2, there was an incremental risk of 
transfer to HD along with faster decline in residual kidney function.
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An increased risk of peritonitis-associated hospitalization was also observed in higher BMI, 
but the lack of significant association in each category may be attributed to the limited 
number of events captured in our administrative dataset. Peritonitis-related hospitalization 
was observed in 8% of the study population, but the overall peritonitis event should be more 
frequent if we accounted for those treated in the outpatient setting. Potential mechanisms 
include protracted wound healing, greater difficulties in the daily care of the exit site, and 
increased susceptibility against skin and soft tissue infection.
The reason for the transfer from PD to HD is often multifactorial, and we were unable to 
identify definite reason(s) for each individual case in the administrative data. However, our 
findings suggested that among patients who transferred to HD, approximately one-fourth of 
them did not reach the minimum solute clearance (i.e., 1.7 of weekly Kt/V)47 during the last 
quarter of PD. Obese patients consistently showed lower Kt/V over time than lean patients 
largely due to the mathematical coupling between BMI and urea distribution volume “V” 
based on actual body weight, which might have led to faster transfer to HD among obese 
patients. However, the Watson formula overestimates V in obese patients, resulting in lower-
than-actual Kt/V.48 KDOQI (Kidney Disease Outcomes Quality Initiative) guidelines 
suggest considering the use of the patient’s ideal (or standard weight)38 or the use of body 
surface area instead of V.47 Another unsolved issue is that we cannot separate the 
contribution of different body compositions (i.e., muscle versus fat) based on the 
anthropometric measures. Further studies are needed to develop a better metric to assess 
dialysis adequacy among PD patients across a wide range of body weights and different 
body compositions.
The association between treatment modality and mortality has been shown to be modified by 
obesity in some studies,24,25 and has also changed over time favoring PD.4,34 Using USRDS 
data between 1995 and 1997, Stack et al. showed a heightened risk of death among PD 
patients with BMI ≥23.5 kg/m2 (versus HD patients in the same BMI categories) while 
comparable survival was observed among those with lower BMI.24 In a previous report from 
our group,25 we found comparable mortality risk among PD and HD patients with BMI ≥35 
kg/m2, and lower mortality risk associated with PD among less obese patients using 
administrative data between 2001 and 2006 from the same dialysis organization. In the 
present study, we examined a more contemporary incident dialysis cohort (2007–2011), and 
consistently observed lower mortality among PD versus HD patients across BMI categories 
in non-diabetic patients. Diabetic PD patients also showed lower mortality compared with 
their diabetic HD counterparts if their BMI was <35 kg/m2, and they had similar mortality 
even in the presence of severe obesity. Advances in PD during these two decades have likely 
contributed to improved survival in the PD population, and might have modified the 
modality-mortality association in obese patients.
We acknowledge several limitations in this study. First, due to the observational nature of 
our study, we can neither exclude the presence of residual confounding and unmeasured 
confounders (i.e., regions,49 socioeconomic status,50 elective outpatient initiation51) nor 
prove causality between obesity and outcomes. Second, there may be selection bias because 
residual renal clearance was not consistently measured in all patients. Specifically, included 
patients were likely to be treated in facilities with more PD experience and to have greater 
Obi et al. Page 8
Am J Kidney Dis. Author manuscript; available in PMC 2019 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
residual kidney function (Table S1), and, hence, our results may not be extrapolated to 
patients who are treated in less experienced facilities or among patients with little or no 
residual kidney function. Third, we did not have post-KTx information. Censoring patients 
at KTx might have resulted in underestimation of mortality risk associated with obesity 
because non-obese patients are more likely to undergo KTx, which substantially improves 
survival of ESRD patients. However, this censoring is unlikely to affect the results of 
survival comparisons between PD versus HD because the relative likelihood of undergoing 
KTx between dialysis modalities are similar across BMI categories.25
In conclusion, obesity is associated with various adverse outcomes among PD patients but 
should not be considered an absolute contraindication to PD given the equivalent mortality 
of obese PD versus HD patients observed in our study. These findings make it imperative to 
implement interventions and strategies that would safely prolong time on PD among obese 
patients, such as larger dwell volumes, frequent evaluation of residual kidney function with 
proper adjustment of PD prescription, as well as prevention of peritonitis and residual 
kidney function decline. Further studies are also needed to test whether successful weight 
reduction reduces PD-related adverse events and enhances the survival advantage of PD 
among obese patients.
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Figure 1. 
Flow diagram summarizing the criteria used to constitute the analytic cohort. 
Abbreviations: PD, peritoneal dialysis; GFR, glomerular filtration rate.
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Figure 2. 
(A) Incidence rate for transfer to HD, all-cause death, and KTx, and the hazard ratios 
for (B) transfer HD, (C) all-cause death, and (D) KTx across six BMI categories among 
15,573 incident PD patients (2007–2011). The association with each outcome was 
estimated with three-level sequential adjustments. Bars represent 95% confidence intervals. 
Abbreviations: BMI, body mass index; HD, hemodialysis; PD, peritoneal dialysis; KTx, 
kidney transplantation.
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Figure 3. 
The association of BMI with incidence rate of (A) peritonitis-related and (B) non-
peritonitis-related hospitalization among 15,573 incident PD patients (2007–2011). 
Incidence rate ratios were estimated with three-level sequential adjustments. Bars represent 
95% confidence intervals. Abbreviations: BMI, body mass index; PD, peritoneal dialysis.
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Figure 4. 
Two-year trajectories of weekly (A) renal ClCr and (B) renal, (C) peritoneal, and (D) 
total Kt/V across BMI categories among 15,573 incident PD patients (2007–2011) 
estimated by linear mixed-effects model with adjustment for case-mix variables. Points 
and bars represent estimates and 95% CIs, respectively. Abbreviations: BMI, body mass 
index; BSA, body surface area; ClCr, creatinine clearance.
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Figure 5. 
The incidence (A–C) and between-group difference (D–F) in all-cause death across 
three BMI categories among 14,007 PD patients vs. 28,014 HD patients matched based 
on BMI, age, sex, race/ethnicity, ESRD reason, Charlson comorbidity index, and 
dialysis vintage. Patients were followed up even after changing modality to either PD or 
HD. The curves were truncated at 4 years given <5% patients remaining at risk. 
Abbreviations: BMI, body mass index; HD, hemodialysis; PD, peritoneal dialysis.
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Table 2
Patient characteristics during last quarter of PD, stratified by outcomes
Variable Transfer to HD Death Kidney Transplant Censoring events
(n=2,568) (n=1,863) (n=1,271) (n=9,871)
BMI (kg/m2) 28 (25 to 33) 27 (24 to 32) 26 (23 to 30) 28 (24 to 32)
Age (years) 57±15 66±13 48±13 57±15
Male sex 58% 61% 59% 57%
Race
  Non-Hispanic white 54% 74% 64% 56%
  Non-Hispanic black 27% 13% 18% 23%
  Hispanic 14% 8% 10% 13%
  Other races 6% 6% 9% 8%
Cause of ESRD
  Diabetes 45% 51% 27% 39%
  Hypertension 28% 26% 22% 28%
  Other causes 27% 23% 51% 33%
Dialysis vintage (months) 17 (11 to 26) 18 (10 to 28) 16 (9 to 26) 18 (9 to 30)
Comorbid conditions
  Diabetes 71% 71% 44% 61%
  Congestive heart failure 15% 13% 3% 6%
  Myocardial infarction 17% 21% 8% 11%
  Other cardiac diseases 20% 20% 10% 12%
  Hypertension 60% 48% 47% 52%
  COPD 4% 4% 1% 2%
No. of Five-year cumulative incident PD patients 31 (18 to 53) 34 (19 to 54) 36 (21 to 55) 32 (17 to 53)
Weekly CLcr
  Renal (L/week) 25 (7 to 55) 15 (0 to 42) 42 (14 to 83) 41 (13 to 79)
  Peritoneal (L/week) 39±13 40±12 35±13 36±13
  Total (L/week) 68 (51 to 93) 60 (48 to 81) 79 (56 to 111) 77 (56 to 111)
  Total <50 L/week (%) 22% 31% 17% 16%
Weekly Kt/V
  Renal 0.5 (0.3 to 1.0) 0.4 (0.2 to 0.9) 0.9 (0.4 to 1.5) 0.8 (0.4 to 1.4)
  Peritoneal 1.5±0.5 1.6±0.4 1.5±0.4 1.5±0.4
  Total 2.0 (1.7 to 2.5) 1.9 (1.7 to 2.3) 2.2 (1.9 to 2.7) 2.2 (1.9 to 2.6)
  Total <1.7 (%) 23% 24% 8% 10%
Laboratory variables
  Hemoglobin (g/dL) 11.2±1.4 11.2±1.4 11.6±1.3 11.0±1.3
  Albumin (g/dL) 3.4±0.5 3.1±0.5 3.8±0.4 3.7±0.5
  Creatinine (mg/dL) 8.3 (5.9 to 11.3) 7.3 (5.3 to 9.5) 8.6 (5.9 to 12.4) 7.7 (5.3 to 10.8)
  Corrected calcium (mg/dL) 9.1±0.7 9.2±0.6 9.2±0.5 9.1±0.6
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Variable Transfer to HD Death Kidney Transplant Censoring events
(n=2,568) (n=1,863) (n=1,271) (n=9,871)
  Phosphorus (mg/dL) 5.5±1.8 5.3±1.6 5.3±1.3 5.1±1.4
  Intact PTH (pg/mL) 314 (203 to 486) 257 (159 to 417) 303 (213 to 457) 332 (213 to 509)
Note: Note: Values for categorical variables are given as percentages; values for continuous variables, as mean ± standard deviation or median 
[interquartile range]. Conversion factors for units: calcium in mg/dL to mmol/L, ×0.2495; creatinine in mg/dL to µmol/L, ×88.4; phosphorus in 
mg/dL to mmol/L, ×0.3229.
Abbreviations: CLcr, creatinine clearance; ESRD, end-stage renal disease; COPD, chronic obstructive pulmonary disease; HD. Hemodialysis; PD, 
peritoneal dialysis; PTH, parathyroid hormone
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